-
Carfilzomib, sold
under the
brand name Kyprolis, is an anti-cancer
medication acting as a
selective proteasome inhibitor. Chemically, it is a tetrapeptide...
-
lenalidomide or pomalidomide), and a
proteasome inhibitor (e.g., or bortezomib,
carfilzomib or ixazomib), in
combination with a
steroid (e.g., dexamethasone). While...
-
parent compound of
multiple myeloma drug
carfilzomib (Kyprolis).
Based on
successful Phase II
trials of
carfilzomib, Onyx
Pharmaceuticals acquired Proteolix...
-
being studied for the
treatment of cancer.
Drugs such as bortezomib,
carfilzomib, and
ixazomib are
already approved for use in
treating multiple myeloma...
-
Tretinoin L01XF02
Alitretinoin L01XF03
Bexarotene L01XG01
Bortezomib L01XG02
Carfilzomib L01XG03
Ixazomib L01XH01
Vorinostat L01XH02
Romidepsin L01XH03 Panobinostat...
-
treatment of last resort) and
breast (in
comparison to capecitabine).
Carfilzomib (marketed
under the
trade name Kyprolis) was
approved by the FDA on June...
- role.
Proteolix built on
technology invented by Dr.
Crews to
develop carfilzomib/Kyprolis®
through mid-phase 2
clinical trials before being acquired by...
- Parkinson's-like
symptoms in rats.
Derivatives of
epoxomicin include carfilzomib. Epoxomicin,
Santa Cruz
Biotechnology Meng, L; Mohan, R; Kwok, BH; Elofsson...
- and a
proteasome inhibitor. It is also
indicated in
combination with
carfilzomib and dexamethasone, for the
treatment of
adults with
relapsed or refractory...
-
product candidate,
carfilzomib (PR-171), is a
tetrapeptide epoxyketone for
treating multiple myeloma, a
blood cancer. The drug
carfilzomib works by preventing...
